CPHRF News and Press, Companhia Siderurgica Paulista Nova Cosipa From 01/21/20

Cipher Pharmaceuticals ( OTC:CPHRF ) reports that Bausch Health Companies (NYSE: BHC ) has notified it that it intends to terminate its license agreement for constipation med Trulance (plecanatide) due to an undisclosed breach of certain provisions of the contract. More news on: Cipher P...

Cipher Pharmaceuticals ( OTC:CPHRF ) has received a Notice of Termination from Bausch Health (NYSE: BHC ) in connection with the License, Development and Commercialization Agreement of Trulance® (plecanatide). More news on: Cipher Pharmaceuticals Inc., Bausch Health Companies Inc., ...

Cipher Pharmaceuticals Receives Notice of Termination from Bausch Canada NewsWire OAKVILLE, ON, Jan. 20, 2020 OAKVILLE, ON , Jan. 20, 2020 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced the Company received a Notice of Term...

Cipher Pharmaceuticals Inc. (CPHRF) Q3 2019 Earnings Conference Call November 07, 2019 08:30 AM ET Company Participants Craig Mull - Interim Chief Executive Officer Nadine Jutlah - Interim Chief Financial Officer Conference Call Participants Prasath Pandurangan - Bloom Burton...

Cipher Pharmaceuticals ( OTC:CPHRF ): Q3 GAAP EPS of -$0.08 misses by $0.12 . More news on: Cipher Pharmaceuticals Inc., Earnings news and commentary, , Read more ...

Cipher Pharmaceuticals Reports Third Quarter 2019 Financial Results Canada NewsWire OAKVILLE, ON, Nov. 7, 2019 Revenue increased 20% to $5.8 million OAKVILLE, ON , Nov. 7, 2019 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announc...

Notice of Cipher Pharmaceuticals Q3 2019 Conference Call Canada NewsWire OAKVILLE, ON, Oct. 24, 2019 OAKVILLE, ON , Oct. 24, 2019 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced the details of its Q3 2019 financial results confer...

Cipher Pharmaceuticals Receives Health Canada Approval For Trulance® (Plecanatide) Canada NewsWire OAKVILLE, ON, Oct. 18, 2019 OAKVILLE, ON , Oct. 18, 2019 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced it has received Heal...

With one product candidate at Phase 3 of development and expecting completion in early 2020, Aclaris Therapeutics ( ACRS ) is a name to be followed carefully. The Phase 3 trial is estimated to be completed on January 15, 2020. With that said, the company’s cash burn rate is very signifi...

Cipher Pharmaceuticals Inc. (OTC:CPHRF) Q2 2019 Earnings Conference Call August 9, 2019 8:30 AM ET Company Participants Craig Mull - Interim Chief Executive Officer Nadine Jutlah - Interim Chief Financial Officer Conference Call Participants Andre Uddin - Mackie Research ...